文献速递慢阻肺

间充质基质细胞:治疗慢性阻塞性肺疾病的新型疗法?

Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease?
PubMed 文献 · Thorax · 2018-04-13

本文综述了间充质基质细胞(MSC)治疗慢性阻塞性肺疾病(COPD)的理论依据与证据。体外细胞培养和动物研究表明,MSC能调节免疫反应并促进组织修复;临床研究已证实MSC治疗的安全性,但尚未提供其在COPD治疗中有效的证据。

要点

  • MSC具有调节免疫反应和促进组织修复的能力。
  • 临床研究已证实MSC治疗COPD的安全性。
  • 目前尚无证据表明MSC治疗COPD有效。

核心结论

  • MSC治疗COPD的安全性已获临床研究证实,但迄今尚未提供其疗效证据。

研究设计与样本

  • 本文为综述,汇总了体外细胞培养研究、体内临床前COPD模型研究及COPD患者临床试验的主要发现。

主要发现

  • 体外细胞培养和动物研究表明MSC能调节免疫反应并促进组织修复。
  • 临床前模型支持MSC可能在COPD中具有临床疗效的假设。
  • 临床试验已证实MSC治疗的安全性,但尚未提供COPD治疗有效的证据。

临床怎么用

  • MSC治疗COPD目前仍属研究性方向,临床决策应以现有证据为基础,不宜将其视为已证实有效的治疗手段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COPD is characterised by tissue destruction and inflammation. Given the lack of curative treatments and the progressive nature of the disease, new treatments for COPD are highly relevant. In vitro cell culture and animal studies have demonstrated that mesenchymal stromal cells (MSCs) have the capacity to modify immune responses and to enhance tissue repair. These properties of MSCs provided a rationale to investigate their potential for treatment of a variety of diseases, including COPD. Preclinical models support the hypothesis that MSCs may have clinical efficacy in COPD. However, although clinical trials have demonstrated the safety of MSC treatment, thus far they have not provided evidence for MSC efficacy in the treatment of COPD. In this review, we discuss the rationale for MSC-based cell therapy in COPD, the main findings from in vitro and in vivo preclinical COPD model studies, clinical trials in patients with COPD and directions for further research.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Broekman W, Khedoe PPSJ, Schepers K, et al. Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease? Thorax. 2018. PMID: 29653970. doi:10.1136/thoraxjnl-2017-210672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。